Home › Funds › Eversept Partners, LP › IONS

Eversept Partners, LP position in IONS

IONIS PHARMACEUTICALS INC · Health Care

Eversept Partners, LP reported holding 664,684 shares of IONS (IONIS PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$52.7M, representing 2.76% of its reported portfolio and ranking #10 among its reported holdings. Eversept Partners, LP has disclosed IONS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)664.68K sh
Reported value held$52.70M
Portfolio Weight2.76%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Eversept Partners, LP's IONS position evolved

Eversept Partners, LP first disclosed a stake in IONS in Q3 2023 at 252,446 shares (US$11.5M). The position peaked in Q2 2026 at 664,684 shares, worth US$52.7M. Across 12 filings, Eversept Partners, LP increased the stake 8 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 664,684 shares valued at US$52.7M — an increase of 32,584 shares quarter over quarter.. Notable position changes include a 29% increase in Q4 2023 (shares fell 14% over the following quarter), a 54% trim in Q4 2024 (shares fell 14% over the following quarter), a 141% increase in Q1 2025 (shares rose 31% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 252.45K $11.45M New
Q4 2023 324.65K $16.42M Add
Q1 2024 376.44K $16.32M Add
Q2 2024 456.88K $21.77M Add
Q3 2024 471.36K $18.88M Add
Q4 2024 214.95K $7.51M Reduce
Q1 2025 517.02K $15.60M Add
Q2 2025 588.90K $23.27M Add
Q3 2025 538.66K $35.24M Reduce
Q4 2025 538.22K $42.58M Hold
Q1 2026 632.10K $47.46M Add
Q2 2026 664.68K $52.70M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About IONS and 13F data

IONS (IONIS PHARMACEUTICALS INC) is a Health Care company. 41 other funds we track also report a position in IONS — the largest reported positions include Two Sigma Investments (US$495.7M), TWO SIGMA ADVISERS, LP (US$241.5M), Tweedy, Browne Co LLC (US$180.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding IONS

All IONS fund holders →

FAQ

How long has Eversept Partners, LP held IONS?

Eversept Partners, LP has disclosed IONS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Eversept Partners, LP's current position in IONS?

As of Q2 2026, Eversept Partners, LP holds 664.68K shares of IONS (IONIS PHARMACEUTICALS INC), valued at $52.70M, representing 2.76% of its reported portfolio and ranking #10.

Has Eversept Partners, LP been buying or selling IONS?

In the latest 13F filing (Q2 2026), Eversept Partners, LP increased its position in IONS. The position peaked in Q2 2026 at 664.68K shares.

Which other funds hold IONS?

Other major institutional holders of IONS include Two Sigma Investments, TWO SIGMA ADVISERS, LP, Tweedy, Browne Co LLC, among 41 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.